Autologous Stem Cell Transplant In Patients With Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)

Summary

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

Eligibility

Age range

Up to 75 years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Etoposide

  BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4

• Drug
  BCNU

  BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6

• Drug
  AraC

  BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2

• Drug
  Melphalan

  BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1

• Procedure
  Peripheral blood stem cell transplantation

  All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.

• Biological
  G-CSF

  All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3

Location